Hmn-372 _top_ Jun 2026

Neuro‑inflammatory pathways are increasingly recognized as central drivers of a spectrum of disorders ranging from Alzheimer’s disease (AD) and Parkinson’s disease (PD) to treatment‑resistant depression and chronic pain. While several biologics have entered the clinic to modulate peripheral inflammation, few agents can cross the blood‑brain barrier (BBB) and selectively silence the intracellular cascades that perpetuate microglial activation.

| Risk | Potential Impact | Mitigation Strategy | |------|------------------|---------------------| | | Failure to achieve statistically significant cognitive or motor benefit could stall approvals | Adaptive trial designs, enrichment for biomarker‑positive subpopulations (elevated CSF IL‑1β) | | Long‑term safety of chronic NLRP3 inhibition | The inflammasome plays a role in host defense; chronic suppression might predispose to infections or malignancy | Ongoing surveillance in registries; periodic immunologic monitoring (e.g., vaccine response) | | Regulatory pathway ambiguity | No precedent for oral NLRP3 inhibitors in CNS indications | Early engagement with FDA/EMA via Breakthrough Therapy and PRIME designations; leverage existing data from peripheral NLRP3 programs | | Competitive landscape | Multiple companies (e.g., Novartis , Roche ) are pursuing NLRP3 inhibitors; some are entering CNS trials | Speed to market, robust biomarker package, and differentiation through BBB penetration and oral formulation | HMN-372

The AAV vector used in HMN-372 is designed to target specific cells, ensuring efficient gene delivery and expression. Once administered, the AAV vector infects the target cells, delivering the therapeutic gene. The gene then integrates into the host genome, allowing for sustained expression of the corresponding protein. This mechanism enables HMN-372 to address the root cause of genetic diseases, providing a potentially curative treatment option. Once administered, the AAV vector infects the target

The potential impact of HMN-372 could be significant, contributing to: The potential impact of HMN-372 could be significant,

HMN-372 is part of a class of small-molecule inhibitors designed to target specific genetic mutations that drive tumor growth. Research suggests it is primarily being evaluated for its efficacy against .